TY - JOUR
T1 - High dose chemotherapy with carboplatin, VP 16 ± ifosfamide in germ cell tumors
T2 - the Italian experience
AU - Rosti, G.
AU - Albertazzi, L.
AU - Salvioni, R.
AU - Valzania, F.
AU - Bassetto, M. A.
AU - Pizzocaro, G.
AU - Marango, M.
PY - 1991
Y1 - 1991
N2 - This schedule has shown an interesting activity with nearly 40% of the patients achieving CR. Moreover 4 patients experienced an inversion rate (CR with ABMT when they never achieved this status before). In terms of toxicity, this schedule seems feasible with 2/28 toxic deaths, which is in the lower part of the range of major solid tumors ABMT programs. But even if the rationale is proper, a better patients' selection is required. The CCR (Continuous Complete Remission) rate is overimposable to other main studies previously published, but all our CCR were obtained in responding patients (Sensitive Relapses or unresectable PR). We may suggest that earlier transplantation is advisable when less tumor bulk is present and less clonal heterogeneity. The exact maximum tolerated dose of Carboplatin/VP 16/ifosfamide programs has not yet been clearly pointed out. The lack of major life-threatening episodes and neuro/nephrotoxicity may allow us to explore higher Carboplatin doses. Anyway the ultimate answer to the utility of ABMT trials must come from a randomized study in responding patients.
AB - This schedule has shown an interesting activity with nearly 40% of the patients achieving CR. Moreover 4 patients experienced an inversion rate (CR with ABMT when they never achieved this status before). In terms of toxicity, this schedule seems feasible with 2/28 toxic deaths, which is in the lower part of the range of major solid tumors ABMT programs. But even if the rationale is proper, a better patients' selection is required. The CCR (Continuous Complete Remission) rate is overimposable to other main studies previously published, but all our CCR were obtained in responding patients (Sensitive Relapses or unresectable PR). We may suggest that earlier transplantation is advisable when less tumor bulk is present and less clonal heterogeneity. The exact maximum tolerated dose of Carboplatin/VP 16/ifosfamide programs has not yet been clearly pointed out. The lack of major life-threatening episodes and neuro/nephrotoxicity may allow us to explore higher Carboplatin doses. Anyway the ultimate answer to the utility of ABMT trials must come from a randomized study in responding patients.
UR - http://www.scopus.com/inward/record.url?scp=0025758845&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025758845&partnerID=8YFLogxK
M3 - Article
C2 - 1652334
AN - SCOPUS:0025758845
VL - 7
SP - 94
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - SUPPL. 2
ER -